Latest Breaking News On - Xianghong lin - Page 1 : comparemela.com

Duality Biologics Completed $90 Million Series B Financing News provided by Share this article Share this article PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ Duality Biologics (DualityBio or Company), an innovative biotech company, announced the completion of $90 million series B financing today. This round of financing was led by Lilly Asia Ventures (LAV) and jointly invested by YUNION Healthcare Fund, Huagai Capital, NRL Capital, Green Pine Capital Partners, and Oriza Holdings, etc. Series A investor WuXi Biologics (2269.HK) continued to increase its stake in this round to accelerate DualityBio s R&D progress leveraging its premier-quality integrated technology platforms. DualityBio has raised more than $120 million since its establishment in January 2020. Major investors in the previous round include King Star Capital, WuXi Biologics, 6 Dimensions Capital, and other investment institutions. The funds raised in this round will be mainly used for

United statesHong kongJohn zhuXianghong linChris chenYi shiHealthcare fundOriza holdingsPrnewswire duality biologics dualitybio or companyLilly asia venturesHuagai capitalGreen pine capital partnersWuxi biologicsKing star capitalNovel modality drugMeet unmet medical